Clinics (n) "147" was revised to "146." Table 3 Column Neurology Females Lyso-Gb3-positive patients (%) "2/227 (0.9)" was revised to "1/226 (0.4)." GLA mutation (%) "1/227 (0.4)" was revised to "1/226 (0.4)."
Column Total Females
Lyso-Gb3-positive patients (%) "15/1,036 (1.4)" was revised to "14/1,035 (1.4)." GLA mutation (%) "6/1,036 (0.6)" was revised to "6/1,035 (0.6)."
Figure 1
We revised Figure 1a and b as follows: Table 3 Frequencies of patients who screened positive for lyso-Gb3 and class 1 GLA mutations, grouped according to the specialty of the referring clinic Figure S2 . Flowchart of the lyso-Gb3 screening and gene analysis in female patients.
We revised Supplementary Figure S2 as follows:
The upper square
Female with clinical symptoms suggestive of Fabry disease; "(n = 1036)" was revised to "(n = 1035)."
Neurology; "(n = 227)" was revised to "(n = 226)."
The second square from the top (left side)
Positive lyso-Gb3 screen; "(n = 15)" was revised to "(n = 14)."
Neurology; "(n = 2)" was revised to "(n = 1)."
The third square from the top (second square from the left)
Normal α-Gal A; "(n = 8)" was revised to "(n = 7)."
Neurology; "(n = 1)" was revised to "(n = 0)."
The fourth square from the top (second square from the left)
"Neurology (n = 1)" was deleted. , and we deleted the dot plot for one female patient in the positive group (plasma lyso-Gb3 7.6 ng ml −1 ). Therefore, the median plasma lyso-Gb3 value of Female Positive was changed from "11.5 ng ml −1 " to "13.3 ng ml −1 ." The position of short horizontal line was also changed. b Female Positive (n = 15) was replaced with (n = 14), and we deleted the dot plot for one female patient in the positive group (plasma α-Gal A activity 4.9 nmol h −1 ml
−1
). Therefore, the median plasma α-Gal A activity value of Female Positive was changed from "4.6 nmol h −1 ml −1 " to "3.9 nmol h −1 ml −1 ." The position of the short horizontal line was also changed.
